Inke has been successfully inspected by every major global authority for a wide array of products (last US-FDA inspection in May 2016).
For the last two decades, the company has made great strides to become a prestige provider of respiratory APIs for inhalation.
Development and manufacturing of high‐added value active substances for
the pharmaceutical industry for use in respiratory and CNS therapies
Quality‐based but competitive philosophy that helps us to establish and develop
stable collaborations with leading companies in Europe, the US, Japan, Korea and China
Own laboratories where professionals with a high level of training
and experience develop and refine the processes for final transfer to Inke's manufacturing plant
Expert in customising products (PSDs) to meet each client's technical and regulatory
needs during the development and commercialisation of its pharmaceuticals
strong reputation and brand image